Potential new treatment for angioimmunoblastic T-cell lymphoma

byUniversity of TsukubaCredit: AI-generated imageA type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from

Updated on: December 18,2023

Potential new treatment for angioimmunoblastic T-cell lymphoma

byUniversity of TsukubaCredit: AI-generated imageA type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from

Updated on:December 18,2023

Study examines causes of death in US breast cancer survivors

byWileyCredit: CC0 Public DomainSurvival rates for patients with breast cancer have improved significantly in the last four decades, and many patients will eventually die from non-cancer-related

Updated on: December 22,2023

Study examines causes of death in US breast cancer survivors

byWileyCredit: CC0 Public DomainSurvival rates for patients with breast cancer have improved significantly in the last four decades, and many patients will eventually die from non-cancer-related

Updated on:December 22,2023

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,

Updated on: December 22,2023

More proof that concurrent use of multiple medications leads to adversity for older cancer patients

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainWhen older adults with cancer take multiple medications—including ordinary drugs like blood pressure pills, supplements,

Updated on:December 22,2023

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

SubscribeDecember 6, 2023, by James H. Doroshow, M.D.Findings from NCI-MATCH and its successor trials will help oncologists implement precision medicine in everyday patient care.Credit: iStockMore tha

Updated on: December 19,2023

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

SubscribeDecember 6, 2023, by James H. Doroshow, M.D.Findings from NCI-MATCH and its successor trials will help oncologists implement precision medicine in everyday patient care.Credit: iStockMore tha

Updated on:December 19,2023

High-dose IV vitamin C plus chemotherapy found to double survival time in advanced pancreatic cancer

by Jennifer Brown,University of IowaGraphical abstract. Credit:Redox Biology(2024). DOI: 10.1016/j.redox.2024.103375Results from a randomized, phase 2 clinical trial show that adding

Updated on: December 01,2024

High-dose IV vitamin C plus chemotherapy found to double survival time in advanced pancreatic cancer

by Jennifer Brown,University of IowaGraphical abstract. Credit:Redox Biology(2024). DOI: 10.1016/j.redox.2024.103375Results from a randomized, phase 2 clinical trial show that adding

Updated on:December 01,2024

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on: December 20,2023

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on:December 20,2023

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on: December 17,2023

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on:December 17,2023

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according

Updated on: December 17,2023

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according

Updated on:December 17,2023

Putting liquid biopsies on solid ground: Cancer diagnosis from a milliliter of blood

byWeizmann Institute of ScienceSingle-molecule DNA sequencing technical setup. Schematic representation of key instrumentation used to perform single-molecule DNA sequencing. Straight and dashed

Updated on: December 19,2023

Putting liquid biopsies on solid ground: Cancer diagnosis from a milliliter of blood

byWeizmann Institute of ScienceSingle-molecule DNA sequencing technical setup. Schematic representation of key instrumentation used to perform single-molecule DNA sequencing. Straight and dashed

Updated on:December 19,2023

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v

Updated on: October 24,2023

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v

Updated on:October 24,2023

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on: December 19,2023

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on:December 19,2023

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on: December 20,2023

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on:December 20,2023